Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury

In this study, an animal model of moderate-severe TBI was treated with an acute dose of propranolol followed by a delayed dose of human mesenchymal stem cells (MSCs), resulting in improved short- and long-term measurements. These results have direct translational application. They reinforce the inevitable clinical trial of MSCs to treat TBI by demonstrating, among other benefits, a notable decrease in chronic neuroinflammation. More importantly, these results demonstrate that MSCs and propranolol, which is increasingly being used clinically for TBI, are compatible treatments that improve overall outcome.

Source: Stem Cells Translational Medicine - January 7, 2016 Category: Stem Cells Authors: Kota, D. J., Prabhakara, K. S., van Brummen, A. J., Bedi, S., Xue, H., DiCarlo, B., Cox, C. S., Olson, S. D. Tags: Tissue-Specific Progenitor and Stem Cells, Mesenchymal Stem Cells Source Type: research